These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 17557945

  • 1. Multitarget tyrosine kinase inhibition: [and the winner is...].
    Verweij J, de Jonge M.
    J Clin Oncol; 2007 Jun 10; 25(17):2340-2. PubMed ID: 17557945
    [No Abstract] [Full Text] [Related]

  • 2. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep 10; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of recent drug approvals on translational research and drug development.
    Atkins MB.
    Clin Adv Hematol Oncol; 2007 Apr 10; 5(4):285-7. PubMed ID: 17607287
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A, López-Ibarra Lozano PJ, Triviño-Ibáñez EM, Escobar-Jiménez F.
    Endocrinol Nutr; 2013 Mar 10; 60(3):152-3. PubMed ID: 22565118
    [No Abstract] [Full Text] [Related]

  • 10. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nishikawa T, Nakano M, Tanabe K.
    Jpn J Clin Oncol; 2010 Dec 10; 40(12):1173-9. PubMed ID: 20696817
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
    Tsuzuki T, Sassa N, Shimoyama Y, Morikawa T, Shiroki R, Kuroda M, Fukatsu A, Kuwahara K, Yoshino Y, Hattori R, Gotoh M.
    Histopathology; 2014 Mar 10; 64(4):484-93. PubMed ID: 24274732
    [Abstract] [Full Text] [Related]

  • 12. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
    Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, Cortesi E.
    Am J Clin Oncol; 2014 Dec 10; 37(6):611-5. PubMed ID: 23388560
    [Abstract] [Full Text] [Related]

  • 13. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI, Whang EE, Lorch JH, Ruan DT.
    Surgery; 2012 Dec 10; 152(6):1142-9. PubMed ID: 23158184
    [Abstract] [Full Text] [Related]

  • 14. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT, Delle Fave G.
    N Engl J Med; 2011 Feb 10; 364(6):564-5. PubMed ID: 21306243
    [No Abstract] [Full Text] [Related]

  • 15. Trials probe new agents for kidney cancer.
    Hampton T.
    JAMA; 2006 Jul 12; 296(2):155-7. PubMed ID: 16835411
    [No Abstract] [Full Text] [Related]

  • 16. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.
    J Clin Endocrinol Metab; 2010 Jun 12; 95(6):2588-95. PubMed ID: 20392874
    [Abstract] [Full Text] [Related]

  • 17. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

  • 18. Editorial comment.
    Rini BI, Shah SN.
    Urology; 2010 May 01; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract] [Full Text] [Related]

  • 19. Editorial comment.
    Vaishampayan U.
    Urology; 2010 May 01; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract] [Full Text] [Related]

  • 20. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
    Rini BI.
    Clin Genitourin Cancer; 2005 Dec 01; 4(3):175-80. PubMed ID: 16425985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.